Stockreport

C4 Therapeutics Details MOMENTUM Phase 2 Start, Eyes Near-Term Decision on EGFR Program at Barclays Confab [Yahoo! Finance]

C4 Therapeutics, Inc.  (CCCC) 
NASDAQ:AMEX Investor Relations: ir.chinacache.com
PDF to enroll 100 patients to detect a =40% response rate , with investigator-assessed responses possible in H2 2027 and centrally assessed readouts around mid-2028. In a [Read more]